- Home
- Automated
- List of product information
- ISENTRESS® 400MG TABLET [SIN13568P]
ISENTRESS® 400MG TABLET [SIN13568P]
Active ingredients: ISENTRESS® 400MG TABLET
Last updated 26 October 2025
On this page
Product Info
ISENTRESS® 400MG TABLET
[SIN13568P]
Product information
Active Ingredient and Strength | RALTEGRAVIR POTASSIUM 434.4 MG EQV FREE PHENOL - 400 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | MSD INTERNATIONAL GMBH (BALLYDINE) - IRELAND |
Registration Number | SIN13568P |
Licence Holder | MSD PHARMA (SINGAPORE) PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J05AX08 |
V. INDICATIONS
Adults
ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.
This indication is based on analyses of plasma HIV-1 RNA levels in three double-blind controlled studies of ISENTRESS. Two of these studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults through 96 weeks and one was conducted in treatment-naïve adults through 240 weeks.
The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response (see VIId. Clinical Studies – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Pediatrics
ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in children and adolescents 2 years of age and older.
This indication is based on the evaluation of safety, tolerability, pharmacokinetic parameters and efficacy of ISENTRESS through at least 24-weeks in a multi-center, open-label, noncomparative study in HIV-1 infected, treatment-experienced children and adolescents 2 to 18 years of age (see VIId. Clinical Studies – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
The safety and efficacy of ISENTRESS 400 mg tablets have not been established in children less than 6 years of age. The safety and efficacy of ISENTRESS chewable tablets have not been established in children less than 2 years of age.
VI. DOSAGE AND ADMINISTRATION
ISENTRESS is to be given in a combination regimen with other antiretroviral agents.
ISENTRESS Film-coated Tablets and Chewable Tablets can be administered with or without food (see VII. Clinical Pharmacology – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
ISENTRESS is available in the following dose strengths:
600 mg film-coated tablet for once daily use
400 mg film-coated tablet for twice daily use
chewable tablet in 100 mg (scored) and 25 mg strengths for twice daily use.
Because the formulations have different pharmacokinetic profiles, do not substitute the 400 mg tablet for the 600 mg tablet to create a 1200 mg once daily dose and do not substitute the chewable tablet for the 400 mg or 600 mg tablet.
The maximum dose of the chewable tablet is 300 mg twice daily.
For the treatment of patients with HIV-1 infection, the dosage of ISENTRESS is as follows:
Adults:
Children and adolescents:
VIII. CONTRAINDICATIONS
ISENTRESS is contraindicated in patients who are hypersensitive to any component of this medicine.